BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2024.10.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Aliya Rashid und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; United States Myeloma Innovations Res…. Hauptthemen laut MEDLINE: Multiple Myeloma, B-Cell Maturation Antigen, Neoplasm, Residual, Immunotherapy, Adoptive. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Recent approvals of chimeric antigen receptor T-cells (CAR T) and bispecific antibody therapies offer new hope for relapsed refractory multiple myeloma (RRMM) patients, with superior efficacy over standard regimens observed in clinical trials. However, relapse after BCMA-directed therapy is common and requires further investigation. PATIENTS AND METHODS: We conducted a retrospective cohort study on 57 RRMM patients treated with BCMA-directed CAR T. Only the patients who had an initial response and lost BCMA-expressing identified PC following CAR T infusion at Day 30 were included in the analysis. Multicolor flow cytometry (MFC) to detect BCMA + plasma cell (PC) re-emergence was performed on bone marrow samples at defined intervals and clinical responses were assessed using International Myeloma Working Group criteria. RESULTS: The majority of patients achieved undetectable BCMA on MFC postinfusion, with subsequent BCMA+ PC re-emergence observed in 55% of cases. Notably, 91% of patients experiencing clinical relapse showed BCMA+ PC re-emergence, often preceding relapse. Early relapse (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS.
- Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS.
- Kansas Institute for Precision Medicine, University of Kansas Medical Center, Kansas City, KS.
- Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS.
- Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS. Electronic address: nahmed…
Förderung
- NIBIB NIH HHS
Zitieren
APA
Rashid, A., Wesson, W., Abdallah, A. O., Snyder, J., Venkatesh, P., Mushtaq, M. U., Shune, L., Witek, M. A., McGuirk, J. P., Soper, S. A., Cui, W., & Ahmed, N. (2025). BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.10.003
Vancouver
Rashid A, Wesson W, Abdallah AO, Snyder J, Venkatesh P, Mushtaq MU, et al. BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2024.10.003
BibTeX
@article{Rashid2025,
author = {Rashid, Aliya and Wesson, William and Abdallah, Al-Ola and Snyder, Jordan and Venkatesh, Priyanka and Mushtaq, Muhammad U and Shune, Leyla and Witek, Malgorzata A and McGuirk, Joseph P and Soper, Steven A and Cui, Wei and Ahmed, Nausheen},
title = {BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2024.10.003}
}
EUVIMED